Response-related predictors of survival in CML / Benjamin Hanfstein, Martin C. Müller, Andreas Hochhaus

The assessment of response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) does not only reflect tumor burden at a given time but has been shown to be linked to long-term survival outcomes as well. Therefore, the quantification of molecular or cytogenetic response as early as 3 months on treatment allows a prognostic stratification of a patient’s individual risk. With competing TKI regimens available, a timely switch of treatment can be considered if unfavorable outcome has to be expected due to early response failure. Numerous studies have demonstrated the association of long-term outcome with early response for first-line treatment with imatinib, with second-generation TKI and for second-line TKI treatment as well.

Saved in:
Persons: Hanfstein, Benjamin [Author]; Müller, Martin Christian [Author]; Hochhaus, Andreas [Author]
Format: eArticle
Publication:April 2015
Part of:Annals of hematology 94(2015), Supplement 2, Seite S227-S239
Notes:Gesehen am 13.11.2017
Physical description:13